Compare Crispr Therapeutics AG (CRSP) vs iShares MSCI South Korea ETF (EWY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares MSCI South Korea ETF — how do they compare? Crispr Therapeutics AG trades at $53.99 (market cap $5.23B), while iShares MSCI South Korea ETF trades at $175.39. The key difference: iShares MSCI South Korea ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | EWY | |
|---|---|---|
Market Cap | $5.23B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $76.78 | $219.20 |
52-Week Low | $44.34 | $71.22 |
Enterprise Value | $3.65B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
EWY trades at $175.21, up 7.41% over the past 24 hours, showing strong momentum amid volatile South Korean market conditions. The ETF exhibits mixed technical signals with bullish moving averages but neutral oscillators, while support and resistance levels indicate potential consolidation between $166 and $172. Recent news highlights significant volatility in South Korean equities driven by AI and semiconductor sector turbulence, with foreign investors rotating capital away from Asian markets.
The outlook remains cautious as EWY faces headwinds from concentrated exposure to South Korea's volatile semiconductor sector, though government support initiatives and Goldman Sachs' bullish 90% upside projection offer potential catalysts. Key risks include continued foreign capital outflows, leveraged ETF speculation concerns, and dependence on AI-driven market swings that have caused recent sharp declines in major holdings like Samsung and SK Hynix.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →
